BTG builds interventional medicine platform with deals

LONDON (Reuters) – Britain’s BTG said it would make two acquisitions, one extending its expertise in liver cancer and the other a treatment for severe blood clots, to create an interventional medicine business with potential sales of $1 billion. The company said on Thursday it had agreed to buy the targeted therapies division of Nordion Inc, for about $200 million in a deal that adds Therasphere radioactive glass beads treatment for liver cancer to its chemotherapy beads unit. …